J

Johnson & Johnson

Makes prescription drugs and medical devices

Product Lead Engineer

Full-TimeUpdated Deadline 11/2/26
No salary listed
Senior
Bachelor's
São José dos Campos, Sao Jose dos Campos - State of São Paulo, Brazil
HybridHybrid work based in São José dos Campos, Brazil.
Software Engineering

About the job

Requirements
  • A bachelor's degree in Computer Science, Information Systems, Engineering, or a related field is required.
  • At least 5 years of experience in software engineering, platform engineering, systems integration, or enterprise technology delivery is required.
  • Experience serving as a Lead Engineer, Technical Lead, Solution Lead, or Engineer in a complex technology environment is required.
  • Experience supporting Talent Acquisition, recruiting, Human Capital Management, or HR technology solutions is required.
  • Strong expertise in APIs, integrations, cloud technologies, enterprise application architecture, and modern software engineering practices is required.
  • Experience working within Agile product delivery models and cross-functional product teams is required.
  • Advanced English is required.
  • Demonstrated ability to translate business requirements and customer needs into scalable technical solutions is required.
Responsibilities
  • Serve as the technical authority for assigned Talent Acquisition products and platforms.
  • Define and communicate technical vision, solution strategy, and architectural direction for assigned products.
  • Translate business requirements, user stories, and recruiting process needs into scalable, secure, and sustainable technical solutions.
  • Guide engineers and internal and external delivery teams through complex technical challenges, architectural decisions, and solution implementation approaches.
  • Conduct technical design reviews, code reviews, solution assessments, and engineering reviews to ensure quality, maintainability, scalability, and security.
  • Establish and promote engineering standards, best practices, and reusable patterns across Talent Acquisition solutions.
  • Partner with Product Owners, vendors, and Architects to balance business priorities, technical feasibility, and long-term platform sustainability.
  • Drive management and reduction of technical debt while continuously improving engineering quality and platform health.
  • Partner with Product Owners, Product Analysts, vendors, and business stakeholders to translate business objectives into technical requirements and solution designs.
  • Drive technical delivery of capabilities supporting recruiting, candidate relationship management, interview experiences, hiring workflows, onboarding, analytics, and AI-enabled recruiting solutions.
  • Ensure solutions align with enterprise architecture standards, cybersecurity requirements, data governance policies, privacy requirements, and compliance expectations.
  • Design scalable and reusable solutions that support global Talent Acquisition processes.
  • Evaluate solution alternatives and recommend technical approaches, platforms, integrations, and emerging technologies.
  • Support modernization initiatives that improve platform flexibility, maintainability, performance, and user experience.
  • Provide technical leadership and engineering oversight across Agile product teams supporting Talent Acquisition and My Joining experiences.
  • Support backlog refinement and provide technical input into prioritization, sequencing, estimates, and acceptance criteria.
  • Ensure solutions are delivered with appropriate testing, automation, documentation, quality controls, release readiness, and operational support models.
  • Identify and resolve technical risks, dependencies, constraints, and impediments affecting delivery.
  • Collaborate across squads, vendor teams, and platform teams to manage cross-team dependencies and drive successful outcomes.
  • Promote engineering practices that improve delivery quality, reliability, security, and speed.
  • Design and provide technical oversight for integrations between Talent Acquisition platforms and enterprise systems, including HR, identity management, analytics, AI, and third-party solutions.
  • Collaborate with Enterprise Architecture and platform teams to align solutions with approved technology standards and future-state architecture.
  • Ensure effective API design, integration patterns, data exchange mechanisms, and nonfunctional requirements across the Talent Acquisition ecosystem.
  • Evaluate emerging technologies and recommend solutions that improve recruiter productivity, hiring efficiency, candidate experience, and operational performance.
  • Contribute technical expertise to architecture reviews and enterprise technology discussions affecting Talent Acquisition products.
  • Help ensure platform stability, reliability, scalability, performance, observability, and security.
  • Monitor production health and partner with support teams to drive incident resolution, root-cause analysis, and preventive improvements.
  • Drive automation, DevOps practices, and continuous improvement across the solution lifecycle.
  • Support technology lifecycle management, including upgrades, vulnerability remediation, compliance activities, resiliency testing, and modernization.
  • Define and monitor technical metrics, service levels, quality measures, and operational performance indicators.
  • Collaborate with technology suppliers and implementation partners to support successful solution delivery and platform operations.
  • Evaluate supplier platform roadmaps, technical capabilities, integration approaches, and solution risks.
  • Participate in solution assessments, proofs of concept, and technology evaluations.
  • Provide technical expertise during product selection, implementation planning, build-versus-buy analysis, and platform enhancement initiatives.
Desired Qualifications
  • Experience with Workday Recruiting, Workday Extend, Beamery, Eightfold AI, Paradox, HireVue, LinkedIn Talent Solutions, SeekOut, or similar Talent Acquisition platforms.
  • Experience implementing AI-enabled recruiting, search, matching, screening, and automation capabilities.
  • Experience integrating HR, Talent Acquisition, identity management, analytics, and third-party technology platforms.
  • Knowledge of recruiting processes, candidate lifecycle management, and Talent Acquisition operations.
  • Experience supporting global enterprise technology solutions in regulated environments.
  • Familiarity with CI/CD pipelines, DevOps practices, test automation, cloud-native architectures, and modern integration patterns.
  • Strategic thinking and strong business and technology acumen.
  • Ability to influence technical direction and engineering decisions across business, vendors, and technology stakeholders.
  • Ability to communicate complex technical concepts clearly to technical and nontechnical audiences.
  • Sound judgment in balancing innovation, quality, security, scalability, cost, and operational stability.
  • Ability to build alignment across cross-functional teams through collaboration, expertise, and trusted technical leadership.
  • Ability to champion engineering excellence, continuous improvement, customer focus, and a culture of quality.
  • Willingness to continuously learn and apply emerging technologies to improve business outcomes and user experiences.
  • Preferred skills include Agile Product Development, Analytical Reasoning, Coaching, Collaboration, Competitive Landscape, Critical Thinking, Customer Alignment, Demand Forecasting, Human-Computer Interaction, Organizing, Product Development, Product Improvements, Product Strategies, Requirements Analysis, Research and Development, Software Development Life Cycle, Software Development Management, Stakeholder Management, Technical Credibility, Technical Writing, and Technologically Savvy.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
Associated Press
Oct 27th, 2026
Pomerantz investigates Johnson & Johnson after 5.73% share drop on talc charges and MedTech miss

Pomerantz LLP is investigating whether Johnson & Johnson (J&J) and some of its officers or directors engaged in securities fraud or other unlawful business practices. The law firm advises affected investors to contact Danielle Peyton at [email protected]. On October 13, 2026, J&J reported third-quarter GAAP net earnings of $210 million, or $0.09 per share. Multi-billion dollar special charges tied to its talc litigation settlement weighed on the result. Its MedTech segment grew only 2.5% to $8.64 billion, a second straight revenue miss. J&J cited pricing constraints in China and disruption in the Middle East. The stock fell $15.12, or 5.73%, to close at $248.61 that day.

Yahoo Finance
Oct 27th, 2026
J&J sees $34.7M net ETF outflow, extending selling streak to four days

ETFs sold a net $34.7 million of Johnson & Johnson stock on Friday, October 23, extending a four-day run of net selling. SPY led the move, cutting $34.6 million, or 0.44% of its stake. XLV sold $24.6 million and DIA $6.3 million. More funds bought than sold, with 26 ETFs adding shares and 17 cutting them, but their purchases were smaller. Net outflows were $55.2 million on October 22, $54.1 million on October 21, and $19.8 million on October 20. A net inflow of $38.1 million came on October 19. Johnson & Johnson has a market cap of $641.1 billion. It reported $99.35 billion in trailing-12-month revenue, up 7.0% over one year.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.